A legal challenge filed Monday by two anti-cannabis organizations is targeting the rescheduling order that moved state-licensed medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act - placing the Trump administration's own DOJ action in federal court before the broader rescheduling process has even completed its administrative hearing phase. The petitioners, Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Association (NDASA), filed with the U.S. Court of Appeals for the D.C. Circuit, asking the court to review and set aside the order entirely. The firm carrying the case is Torridon Law PLLC, where former U.S. Attorney General William Barr - who led DOJ during Trump's first term - is a partner.
What the Rescheduling Order Actually Did
Acting Attorney General Todd Blanche's order, announced last month, did something the cannabis industry had been waiting on for years: it immediately reclassified marijuana products regulated under a state medical cannabis license as Schedule III controlled substances, along with any FDA-approved cannabis products. That's not a small procedural step. Schedule I classification had been the statutory foundation for decades of federal enforcement pressure, banking restrictions, and the tax treatment that makes Section 280E so punishing for licensed operators. Schedule III substances are still federally controlled - they're not legal in the same sense that alcohol is - but the designation carries meaningfully different legal weight.
A broader administrative hearing, scheduled for this summer, was set to address rescheduling for adult-use cannabis products as well. That hearing is now operating under a dual shadow: the SAM/NDASA lawsuit on one side, and a House appropriations subcommittee vote last week to block federal officials from taking further steps to carry out rescheduling on the other.
The Legal Argument - and Why It Has Standing Issues Worth Watching
The two-page petition is blunt. It alleges the order violates the Administrative Procedure Act's rulemaking requirements, exceeds the Attorney General's statutory authority under the CSA, and is "arbitrary and capricious." Named defendants are DOJ, DEA, Blanche, and DEA Administrator Terrance Cole. SAM CEO Kevin Sabet framed the action in public-health terms, arguing the order gave federal approval to what he called a new commercial industry selling edible products - cookies, gummies, beverages - with high-potency cannabis.
Here's the catch, though: standing in federal court requires demonstrating concrete harm. SAM had announced in January that it was retaining Barr's firm specifically to fight rescheduling after Trump signed an executive order directing officials to complete the process quickly. The organizations will need to persuade the D.C. Circuit that they have been sufficiently "aggrieved" by the reform - a bar that courts take seriously in administrative law challenges. Whether the petitioners clear that threshold will be an early test of whether this case proceeds on the merits or stalls at the gate.
The Barr connection is, to put it plainly, an awkward one for an administration that announced the rescheduling in the first place. A law firm where a former Trump-era attorney general is a partner is now suing Trump's own DOJ over a policy Trump's own executive order accelerated. That's not a contradiction that resolves itself easily.
What This Means for Operators and the Supply Chain
For dispensary operators, multi-state operators, cannabis brands, and the wholesalers and distributors running product through licensed medical supply chains, the legal uncertainty is the operational problem - not just a policy footnote. Businesses that had begun adjusting compliance strategies, banking relationships, or tax planning assumptions in anticipation of a Schedule III environment now face the possibility that a court could invalidate the order before the administrative process concludes.
The 280E exposure is the most immediate financial pressure point. Under current federal tax law, cannabis businesses operating under Schedule I cannot deduct ordinary business expenses - cost of goods sold aside - because they are deemed to be trafficking a controlled substance with no accepted medical use. A confirmed Schedule III reclassification would remove that statutory basis. But a court injunction or vacatur could snap that exposure right back. Operators who adjusted financial projections on the assumption that relief was locked in should be treating this lawsuit as a genuine risk event, not background noise.
Compliance teams at licensed dispensaries and vertically integrated operators should also be watching what happens with the summer administrative hearing. Even if the Blanche order survives legal challenge, the pathway for adult-use products to reach Schedule III remains open and contested. State-licensed medical cannabis products got an immediate reclassification; adult-use products are still waiting on the hearing outcome - and Congress is now adding its own pressure through the appropriations process.
The Broader Regulatory Signal
What this lawsuit illustrates - independent of how the court rules - is that federal cannabis policy remains a contested space where administrative actions can be challenged quickly and from unexpected directions. The industry has spent years operating under the assumption that rescheduling would require sustained federal agency effort and political will. The Blanche order moved faster than most expected. The legal response moved even faster.
For investors, payment providers considering cannabis-sector exposure, and software vendors building compliance infrastructure for licensed operators, the lesson is the same one the industry has learned repeatedly: do not price certainty into a regulatory environment that has not reached statutory finality. The Schedule III designation may hold. It may not. Right now, it's in court.
